SIRPA and breast cancer: In order to target the activated immune cells towards breast cancer cells, the study had employed anti-CD47 antibodies that will effectively inhibit the activation of the CD47- signal regulatory protein-α (SIRPα) pathway, which confers protection to the cancer cells against detection and elimination by immune cells.